Institute for Clinical and Economic Review, Boston, MA.
Division of General Internal Medicine and Philip R. Lee Institute for Health Policy Studies, University of California, San Francisco.
J Manag Care Spec Pharm. 2021 Jul;27(7):961-966. doi: 10.18553/jmcp.2021.27.7.961.
Funding for this summary was contributed by Arnold Ventures, California Health Care Foundation, The Donaghue Foundation, Harvard Pilgrim Health Care, and Kaiser Foundation Health Plan to the Institute for Clinical and Economic Review (ICER), an independent organization that evaluates the evidence on the value of health care interventions. ICER's annual policy summit is supported by dues from AbbVie, Aetna, America's Health Insurance Plans, Anthem, Alnylam, AstraZeneca, Biogen, Blue Shield of CA, Boehringer-Ingelheim, Cambia Health Services, CVS, Editas, Evolve Pharmacy, Express Scripts, Genentech/Roche, GlaxoSmithKline, Harvard Pilgrim, Health Care Service Corporation, HealthFirst, Health Partners, Humana, Johnson & Johnson (Janssen), Kaiser Permanente, LEO Pharma, Mallinckrodt, Merck, Novartis, National Pharmaceutical Council, Pfizer, Premera, Prime Therapeutics, Regeneron, Sanofi, Spark Therapeutics, uniQure, and United Healthcare. Agboola, McKenna, and Pearson are employed by ICER. Lin and Kazi received funding from ICER for work on this report.
本摘要的资助由 Arnold Ventures、加州医疗保健基金会、Donaghue 基金会、哈佛朝圣者健康保险和 Kaiser 基金会健康计划提供给临床与经济评价研究所（ICER），这是一个独立评估医疗保健干预措施价值的证据的组织。ICER 的年度政策峰会得到了 AbbVie、Aetna、美国健康保险计划、Anthem、Alnylam、阿斯利康、Biogen、加州蓝盾、勃林格殷格翰、Cambia 健康服务、CVS、Editas、Evolve Pharmacy、Express Scripts、Genentech/Roche、葛兰素史克、哈佛朝圣者、医疗保健服务公司、HealthFirst、Health Partners、Humana、强生（杨森）、Kaiser 永久、LEO 制药、美纳里克斯、默克、诺华、国家制药理事会、辉瑞、Premera、Prime Therapeutics、Regeneron、赛诺菲、Spark Therapeutics、uniQure 和 United Healthcare 的会费支持。Agboola、McKenna 和 Pearson 受雇于 ICER。Lin 和 Kazi 因参与本报告的工作而从 ICER 获得了资金。
